We are live on
!
Find out more
EARNEST Partners Portfolio holdings
AUM
$27.7B
Turnover
6.77%
1-Year Est. Return
52.44%
This Fund
S&P 500
This Quarter
Est. Return
+7.57%
1 Year Est. Return
+52.44%
3 Year Est. Return
+92.17%
5 Year Est. Return
+120.28%
10 Year Est. Return
+519.8%
AUM
$10B
AUM Growth
+$518M
(+5.4%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-1.05%
Top 10 Holdings %
Top 10 Hldgs %
18.87%
Holding
233
New
8
Increased
78
Reduced
133
Closed
4
Avg Time Held
3.1
years
Top 10 Avg Time Held
1.8
years
Top 20 Avg Time Held
2.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Darling Ingredients
DAR
|
+$67.4M |
| 2 |
EastGroup Properties
EGP
|
+$40.3M |
| 3 |
PENN Entertainment
PENN
|
+$33.5M |
| 4 |
Arrow Electronics
ARW
|
+$32M |
| 5 |
Avnet
AVT
|
+$17.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$99.4M |
| 2 |
TSMC
TSM
|
+$29.1M |
| 3 |
FPO
First Potomac Realty Trust
FPO
|
+$24.9M |
| 4 |
Icon
ICLR
|
+$16.9M |
| 5 |
VWR
VWR Corporation
VWR
|
+$15.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.16% |
| 2 | Industrials | 19.65% |
| 3 | Technology | 15.19% |
| 4 | Healthcare | 13.48% |
| 5 | Consumer Discretionary | 9.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
226
Loews
L
$22.2B
| $214K | ﹤0.01% |
+4,465
| New | +$212K |
2017 Q3
0 quarters
|
|
227
Infosys
INFY
$49.1B
| $198K | ﹤0.01% |
27,140
-400
| -1% | -$3.03K |
2014 Q1
14 quarters
|
|
228
Mattel
MAT
$4.95B
| – | – |
-271,964
| Closed | -$5.86M | – |
|
229
Perrigo
PRGO
$2.29B
| – | – |
-95,923
| Closed | -$7.24M | – |
|
|
230
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
| – | – |
-2,992,743
| Closed | -$99.4M | – |
|
|
PRXL
231
DELISTED
Parexel International Corp
PRXL
| – | – |
-6,195
| Closed | -$538K | – |
|
Similar funds
EARNEST Partners's Q3 2017 Portfolio in Review
As of Q3 2017, EARNEST Partners held 233 positions worth $10B, up 5.4% from $9.52B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
EARNEST Partners's Q3 2017 filing shows 8 new, 78 increased, 133 reduced and 4 closed positions. Its largest new stake was Darling Ingredients: 3,984,504 shares worth $69.8M. The largest sale was Teva Pharmaceutical Industries Limited, an estimated $99.4M.
By sector, the portfolio is most concentrated in Financials at 23% of assets, down from 23% a quarter earlier, followed by Industrials and Technology.
- EARNEST Partners's largest Q3 2017 buy was Darling Ingredients: 3,984,504 shares worth $69.8M.
- EARNEST Partners added most to Core Laboratories in Q3 2017, an estimated $11.2M increase.
- EARNEST Partners's biggest Q3 2017 reduction was TSMC, cutting an estimated $29.1M.
- EARNEST Partners fully exited Teva Pharmaceutical Industries Limited in Q3 2017, selling an estimated $99.4M.
- EARNEST Partners's ten largest holdings make up 19% of its $10B portfolio in Q3 2017.
- EARNEST Partners opened 8 new positions and closed 4 in Q3 2017.
- EARNEST Partners's portfolio value rose 5.4% quarter-over-quarter to $10B.
Based on EARNEST Partners's 13F filing for Q3 2017, filed 14 Nov 2017.